Maravai LifeSciences Named to the 2022 Deloitte Technology Fast 500™ List of Fastest-Growing Companies in North America
17 November 2022 - 9:05AM
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, today announced it ranked 270 on the Deloitte
Technology Fast 500™, a ranking of the 500 fastest-growing
technology, media, telecommunications, life sciences, fintech, and
energy tech companies in North America, now in its 28th year.
"We are honored to be part of this year’s prestigious Fast 500
list, which highlights the outstanding growth trajectory we
achieved from 2018 to 2021, and recognizes the contributions of our
team in driving life sciences innovation over the last several
years,” said Carl Hull, Executive Chairman and Interim CEO of
Maravai. “We are proud of how we have built this organization, and
how we were able to assemble a portfolio of enabling technologies
to support robust growth across our full product offering. This,
coupled with explosive demand for CleanCap®, a critical reagent
that is utilized in the production of a majority of COVID-19 mRNA
vaccines, has enabled this accomplishment. Going forward, we are
investing in operational excellence, innovation and our people to
ensure we continue to deliver on our mission of providing enabling
technologies for scientists to bring the miracles of science to
life."
About the 2022 Deloitte Technology Fast 500™Now
in its 28th year, the Deloitte Technology Fast 500 provides a
ranking of the fastest-growing technology, media,
telecommunications, life sciences, fintech, and energy tech
companies — both public and private — in North America. Technology
Fast 500 award winners are selected based on percentage fiscal year
revenue growth from 2018 to 2021.
In order to be eligible for Technology Fast 500 recognition,
companies must own proprietary intellectual property or technology
that is sold to customers in products that contribute to a majority
of the company’s operating revenues. Companies must have base-year
operating revenues of at least US$50,000, and current-year
operating revenues of at least US$5 million. Additionally,
companies must be in business for a minimum of four years and be
headquartered within North America.
About MaravaiMaravai is a leading life sciences
company providing critical products to enable the development of
drug therapies, diagnostics, and novel vaccines and to support
research on human diseases. Maravai’s companies are leaders in
providing products and services in the fields of nucleic acid
synthesis and biologics safety testing to many of the world’s
leading biopharmaceutical, vaccine, diagnostics, and cell and gene
therapies companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
About DeloitteDeloitte refers to one or more of
Deloitte Touche Tohmatsu Limited, a UK private company limited by
guarantee (“DTTL”), its network of member firms, and their related
entities. DTTL and each of its member firms are legally separate
and independent entities. DTTL (also referred to as “Deloitte
Global”) does not provide services to clients. In the United
States, Deloitte refers to one or more of the US member firms of
DTTL, their related entities that operate using the “Deloitte” name
in the United States and their respective affiliates. Certain
services may not be available to attest clients under the rules and
regulations of public accounting. Please see
www.deloitte.com/about to learn more about our global network
of member firms.
Contact Information:
Media Contact:
Sara Michelmore
MacDougall Advisors
+1 781-235-3060
maravai@macdougall.bio
Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2024 to May 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From May 2023 to May 2024